|
Valoración de DCF de Intellia Therapeutics, Inc. (NTLA)
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Intellia Therapeutics, Inc. (NTLA) Bundle
¿Busca evaluar el valor intrínseco de Intellia Therapeutics, Inc.? Nuestra calculadora DCF (NTLA) integra datos del mundo real con extensas funciones de personalización, lo que le permite refinar sus pronósticos y tomar decisiones de inversión más informadas.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 58.0 | 33.1 | 52.1 | 36.3 | 57.9 | 64.2 | 71.3 | 79.1 | 87.7 | 97.3 |
| Revenue Growth, % | 0 | -43.01 | 57.69 | -30.4 | 59.55 | 10.96 | 10.96 | 10.96 | 10.96 | 10.96 |
| EBITDA | -130.3 | -261.0 | -450.6 | -506.3 | -524.0 | -64.2 | -71.3 | -79.1 | -87.7 | -97.3 |
| EBITDA, % | -224.63 | -789.52 | -864.51 | -1395.77 | -905.33 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | 6.3 | 6.9 | 7.6 | 9.0 | 10.3 | 11.4 | 12.7 | 14.0 | 15.6 | 17.3 |
| Depreciation, % | 10.88 | 20.85 | 14.53 | 24.74 | 17.77 | 17.75 | 17.75 | 17.75 | 17.75 | 17.75 |
| EBIT | -136.6 | -267.9 | -458.2 | -515.3 | -534.3 | -64.2 | -71.3 | -79.1 | -87.7 | -97.3 |
| EBIT, % | -235.51 | -810.37 | -879.04 | -1420.51 | -923.1 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 597.4 | 1,086.0 | 1,262.0 | 912.2 | 601.5 | 64.2 | 71.3 | 79.1 | 87.7 | 97.3 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 2.1 | 2.0 | 3.8 | 36.5 | 8.5 | 16.9 | 18.8 | 20.8 | 23.1 | 25.7 |
| Account Receivables, % | 3.67 | 6.14 | 7.23 | 100.5 | 14.72 | 26.35 | 26.35 | 26.35 | 26.35 | 26.35 |
| Inventories | -19.1 | -337.4 | -69.3 | .0 | .0 | -29.9 | -33.2 | -36.8 | -40.9 | -45.4 |
| Inventories, % | -33.01 | -1020.67 | -133.03 | 0 | 0 | -46.6 | -46.6 | -46.6 | -46.6 | -46.6 |
| Accounts Payable | 10.5 | 9.7 | 5.2 | 7.5 | 14.6 | 13.2 | 14.7 | 16.3 | 18.1 | 20.0 |
| Accounts Payable, % | 18.04 | 29.2 | 9.89 | 20.54 | 25.21 | 20.58 | 20.58 | 20.58 | 20.58 | 20.58 |
| Capital Expenditure | -3.6 | -12.8 | -58.4 | -14.0 | -14.0 | -26.6 | -29.6 | -32.8 | -36.4 | -40.4 |
| Capital Expenditure, % | -6.18 | -38.59 | -112.03 | -38.55 | -24.16 | -41.5 | -41.5 | -41.5 | -41.5 | -41.5 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -127.8 | -259.7 | -473.6 | -515.3 | -534.3 | -63.0 | -69.9 | -77.6 | -86.1 | -95.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -97.6 | 52.0 | -798.7 | -620.0 | -502.9 | -58.1 | -83.9 | -93.1 | -103.4 | -114.7 |
| WACC, % | 10.99 | 11.01 | 11.04 | 11.04 | 11.04 | 11.02 | 11.02 | 11.02 | 11.02 | 11.02 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -324.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -117 | |||||||||
| Terminal Value | -1,296 | |||||||||
| Present Terminal Value | -769 | |||||||||
| Enterprise Value | -1,093 | |||||||||
| Net Debt | 21 | |||||||||
| Equity Value | -1,114 | |||||||||
| Diluted Shares Outstanding, MM | 99 | |||||||||
| Equity Value Per Share | -11.27 |
What You Will Get
- Pre-Filled Financial Model: Intellia Therapeutics’ actual data allows for accurate DCF valuation.
- Full Forecast Control: Modify revenue growth, profit margins, discount rates, and other essential metrics.
- Instant Calculations: Real-time updates provide immediate feedback as adjustments are made.
- Investor-Ready Template: A polished Excel file crafted for high-quality valuation presentations.
- Customizable and Reusable: Designed for adaptability, enabling repeated use for in-depth forecasts.
Key Features
- Comprehensive DCF Analysis Tool: Offers in-depth unlevered and levered DCF valuation frameworks tailored for Intellia Therapeutics, Inc. (NTLA).
- WACC Estimator: Pre-configured Weighted Average Cost of Capital sheet with adjustable parameters specific to the biotech sector.
- Customizable Forecast Variables: Adjust growth projections, R&D expenses, and discount rates to align with market conditions.
- Integrated Financial Metrics: Evaluate profitability, leverage, and operational efficiency ratios pertinent to Intellia Therapeutics, Inc. (NTLA).
- Interactive Dashboard and Graphs: Visual representations that encapsulate essential valuation indicators for straightforward interpretation.
How It Works
- Step 1: Download the prebuilt Excel template featuring Intellia Therapeutics’ data.
- Step 2: Review the pre-filled sheets to familiarize yourself with the essential metrics.
- Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Immediately see recalculated results, including Intellia Therapeutics’ intrinsic value.
- Step 5: Utilize the outputs to make informed investment decisions or create reports.
Why Choose Intellia Therapeutics, Inc. (NTLA)?
- Innovative Solutions: Leverage cutting-edge gene editing technologies that are at the forefront of medicine.
- Commitment to Safety: Rigorous testing and compliance ensure the highest standards in patient care.
- Expert Team: Benefit from a team of industry leaders dedicated to advancing therapeutic options.
- Robust Pipeline: A diverse range of therapies in development targeting various genetic diseases.
- Proven Track Record: Backed by successful collaborations and partnerships in the biotech space.
Who Should Use Intellia Therapeutics, Inc. (NTLA)?
- Investors: Gain insights into cutting-edge gene editing technologies to make informed investment choices.
- Biotech Analysts: Streamline your analysis with comprehensive data on Intellia's pipeline and market potential.
- Healthcare Consultants: Efficiently modify reports or presentations to highlight Intellia's innovations for clients.
- Life Sciences Enthusiasts: Enhance your knowledge of gene therapies and their implications through real-world case studies.
- Educators and Students: Utilize it as a valuable resource for understanding biopharmaceutical advancements in academic settings.
What the Template Contains
- Comprehensive DCF Model: Editable template featuring detailed valuation calculations tailored for Intellia Therapeutics, Inc. (NTLA).
- Real-World Data: Intellia's historical and projected financials preloaded for in-depth analysis.
- Customizable Parameters: Modify WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns providing deeper insights into the company's performance.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage metrics specific to Intellia Therapeutics, Inc. (NTLA).
- Dashboard with Visual Outputs: Charts and tables designed for clear, actionable insights and results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.